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ABSTRACT 
Objective: To develop a simple, selective and precise stability indicating reverse-phase high performance liquid chromatography method for the 
simultaneous estimation of atorvastatin calcium and ezetimibe hydrochloride in bulk and tablet dosage form.  
Methods: The chromatographic separation was performed by Agilent Zorbax column (250×4.6 mm, 5 µm) using methanol: 0.1 % v/v 
orthophosphoric acid in water (65:35) as mobile phase at flow rate of 1.0 ml/min with injection volume 20 µl and the detection was carried out 
using UV detector at 240 nm. The method was validated as per ICH guidelines.  
Results: The retention time for atorvastatin calcium (ATV) and ezetimibe hydrochloride (EZT) was found to be 6.81 min and 4.96 min respectively. 
The linear regression analysis data for the calibration plots showed good linear relationship in the concentration range of 5-50 µg/ml for both ATV 
and EZT. The percentage recoveries of ATV and EZT in the marketed dosage form were found to be 100.82 and 94.27 respectively. The correlation 
coefficients for ATV and EZT were 0.9983 and 0.998 respectively. The percentage degradation at different stress conditions like acid, alkaline, 
oxidative and photolytic for atorvastatin calcium were found to be 14.91, 8.26, 8.02 and 2.65 respectively and for ezetimibe hydrochloride, found to 
be 9.70, 32.18, 2.51 and 0.16 respectively.  
Conclusion: The developed method was successfully validated as per ICH guidelines. This method is simple, selective, linear, precise, accurate and 
sensitive, and can be used for routine analysis of tablet dosage forms containing both the drugs. 
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INTRODUCTION 
Anti-hyperlipidemic drugs are classified into various categories each 
acting through different mechanism enhancing each other’s effect such 
as bile acid sequestrates reduce plasma low-density lipoprotein (LDL) 
levels by indirectly increasing the rate of LDL clearance, as a result of 
increased LDL receptors, from the bloodstream. These drugs are not 
orally absorbed and act locally in the gastrointestinal tract by binding 
with glycocholic acid and taurocholic acid, thereby increasing fecal 
excretion. HMG-CoA reductase inhibitors inhibit the rate-limiting step 
in cholesterol biosynthesis, enhance receptor-mediated LDL uptake 
and reduce very low-density lipoprotein (VLDL) precursors [1, 2]. Acyl 
Coenzyme A-Cholesterol Acyltransferase (ACAT) inhibitors bind to a 
specific transport protein located in the wall of the small intestine 
resulting in a reduction of cholesterol transport and absorption [3]; 
thereby lower plasma cholesterol levels by inhibiting the absorption of 
cholesterol at the brush border of the intestine [1]. Fibrates decrease 
plasma cholesterol levels and significantly decrease VLDL levels and 
has variable effect on LDL, such as in patients with 
hypertriglyceridemia, it raises LDL level while in patients with normal 
triglyceride levels, it lowers LDL level; nicotinic acid inhibits lipolysis 
in adipose tissue, initially resulting in sequential events that cause 
reduction in plasma triglycerides and cholesterol, and also decreases 
mobilization of free fatty acids, thus reducing plasma levels.  
Atorvastatin calcium (ATV), is (βR, 8R)-2-(4-fluorophenyl)-α, δ-
dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-
1-H-pyrrole-1-heptanoic acid calcium salt (2:1) trihydrate (fig. 1). It 
is a member of the class of statins used primarily for reducing the 
blood cholesterol and to prevent associated events of cardiovascular 
diseases. Atorvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase which catalyses the conversion of HMG-CoA to 
mevalonate, in the rate-determining step in biosynthesis of 
cholesterol [4, 5]. ATV calcium typical dose is 10-80 mg per day, 
which reduces LDL levels by 40-60%.  
Ezetimibe hydrochloride (EZT), is ((3R, 4S)-1-(4-fluorophenyl)-3-
[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-
azetidinone hydrochloride (fig. 1). It acts by reducing the absorption 
of cholesterol through the intestinal wall, from dietary and biliary 
sources. This leads to the reduction in delivery of cholesterol to the 
liver and hence promotes the synthesis of LDL receptors resulting in 
reduction in serum LDC-C [6]. Co-administration of ATV and EZT 
produces similar effect as that of high dose ATV (80 mg) monotherapy. 
Both ATV and EZT act by different mechanisms to reduce cholesterol 
levels in blood. Several analytical methods have been reported in the 
literature for the analysis of ATV [7-11] and EZT [12-16] individually 
and in combination [17-26] in pharmaceutical dosage forms. 
 
 
Fig. 1: Chemical structures of atorvastatin calcium nd Ezetimibe 
 
Some of the reported methods require SPE, evaporation, and other 
time-consuming preparation steps or expensive equipment that are 
not economically feasible for routine use in pharmacokinetic and 
pharmaceutical studies in which more number of samples are 
analyzed. Frequent clinical use of these two agents in combination 
provides a provision or the development of an analytical method for 
simultaneous analysis of ATV and EZT in pharmaceutical dosage 
form. The Liquid Chromatography with UV detection offers an 
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important advantages such as rapid set-up of instrumentation, 
versatility, and low cost and it has been proved to be a valuable 
method in the QC of drug compounds [27].  
The literature survey revealed that there is no sensitive, simultaneous 
determination method on ATV and EZT in combined dosage forms. Till 
date no detailed report on the forced degradation studies on this 
combination under the mild stress conditions to resolve the drug from 
its potential impurities and degradation products. No interference of 
impurities and degradation products was observed during method 
development. Therefore, the aim of the present study was the 
development and validation of a simple, accurate, precise, stability-
indicating, reliable and cost-effective RP-HPLC method for the 
simultaneous estimation of ATV and EZT in a combined commercial 
tablet form. Stability tests are performed on both drug substances as per 
International Conference on Harmonization (ICH) norms. 
MATERIALS AND METHODS 
Chemicals and reagents 
ATV and EZT, in its pure form, were gifted by Biocon Ltd., Bangalore, 
India. Methanol and water of HPLC grade were purchased from S D-Fine 
Chemicals Ltd., Mumbai, India. Orthophosphoric acid and triethylamine 
were of analytical reagent grade. Methanol and water as a mixture, in the 
ratio of 1:1, was used as diluent to prepare working solutions of required 
concentrations. All the stock and working solutions were protected from 
sunlight and stored in a refrigerator at 4 °C. 
Equipment and chromatographic conditions 
A Shimadzu Separation Module LC-10AT HPLC, used for method 
development, forced degradation studies and method validation, 
equipped with VP Binary pump LC-10ATvp pump, SIL-10ADvp auto-
sampler, CTO-10Avp column temperature oven, SPD-10Avp UV-
Visible detector. All the components of the system are controlled 
using SCL-10Avp system controller. Data acquisition was carried out 
using LC solutions version 1.23 SP 1 software. Chromatographic 
separations were carried out using Agilent Zorbax column (150×4.6 
mm, 5 µm), at room temperature (25 °C). The chromatograms were 
recorded, and the peaks were quantified using an automatic 
integrator. In this method, 1.0 ml/min flow rate was used for the 
separation with detection at 240 nm. The injection volume was 20 µl. 
Preparation of standard solutions 
Stock standard solutions of ATV and EZT were prepared with 
diluent at concentrations of approximately 1000 µg/ml for ATV and 
EZT, each. Both solutions were confined to the dark and used within 
24 h to avoid decomposition. The concentrations of ATV and EZT 
varied in the range of 5-50 µg/ml each. The calibration curves for LC 
analysis were constructed by plotting the peak area of the drug to 
that corresponding drug concentration. 
Generation of stressed samples for establishment of the 
stability-indicating assay 
Degradation studies were performed with stress conditions of acid 
and base hydrolysis, oxidation and photolysis, to evaluate the ability 
of the proposed method to separate ATV and EZT from their 
degradation products [28]. The optimized method was used to study 
the stress degradation behavior of ATV and EZT and may be 
applicable in stability testing of pharmaceutical dosage forms of 
routine analysis. The reactions were carried out at drug 
concentrations each 25 µg/ml of ATV and EZT. The stressed 
conditions were as follows: hydrolytic conditions-acidic hydrolysis, 
drug solution in 0.1 M HCl was exposed for 24 h; alkaline hydrolysis, 
drug solution in 0.1 M NaOH was exposed for 24 h; oxidative 
condition–drug solution in 3% H2O2 
Validation of the developed method 
stored for 24 h; photolytic 
conditions-drug solution was exposed to UV light for 6 h.  
A similar method validation protocol was followed for both drugs. 
System suitability 
The system suitability was assessed by six replicates analyses of both 
drugs at concentrations 25 µg/ml each of ATV and EZT. The % CV of 
peak area and retention time for both drugs ATV and EZT are within 
2% indicating that the suitability of the system (fig. 2 and table 1) [29].  
Specificity 
Specificity is the ability of the method to measure the analyte 
response in the presence of other drugs, excipients and their 
potential impurities (fig. 3) [30-34].  
Linearity 
Linearity of the method was established by triplicate injections of 
the solutions containing the drugs in the range of 5-50 µg/ml for 
each drug. The calibration curves were constructed and the 
acceptable fit to the linear regression was demonstrated and 
reported by the necessary parameters (fig. 4 and 5, table 2) [30-34].  
Accuracy and precision 
To determine the precision, triplicate injections of selected 
concentrations were analyzed, and the values of %RSD were 
calculated. In order to demonstrate applicability and accuracy of the 
proposed method, recovery tests are also carried out by analyzing 
the synthetic mixtures of the ATV and EZT. After five repeated 
experiments, the recoveries from these synthetic mixtures were 
calculated for each compound (table 3).  
Assay of Statix-Ez®
Ten tablets labeled to contain 10 mg of ATV, 10 mg of EZT and 
excipients, were weighed and finely powdered. An accurate amount 
of the powder equivalent to the content of one tablet was weighed, 
transferred into a 10 ml volumetric flask, diluted with diluent, 
stirred for 10 min, and then the volume was adjusted with the same 
diluent. After filtration, appropriate solutions were prepared by 
taking suitable aliquots from clear filtrate solution and were diluted 
with the diluent in order to obtain the final solutions. The content 
amounts of ATV and EZT were calculated from the corresponding 
regression equations. Recovery experiments from tablets also showed 
the reliability and suitability of the method. Accuracy was established 
across the specified range of the analytical procedure. The percentage 
of recovery and RSD were calculated for both the drugs.  
 tablets 
  
Table 1: System suitability studies results of the proposed RP-LC method 
Parameters ATV EZT Recommended value 
Retention time, min 6.81 4.96 - 
Resolution (RS 4.65 ) 0.00 >2 
Theoretical plates (N) 3600.17 3355.17 >2000 
Tailing factor 1.60 (avg) 1.70 (avg) <2 
Peak area 1028365.00 (avg) 1267154.17 (avg) -- 
% RSD (for retention time) 1.80 1.70 <2 




The U. S. Pharmacopeia (USP) suggests that system suitability tests 
be performed prior to analysis. System suitability for the proposed 
method was evaluated. A system suitability test can be defined as a 
test to ensure that the method can generate results of acceptable 
accuracy and precision. The requirements for system suitability are 
usually designed after method development. And also the method 
developed has been validated as per ICH guidelines. The parameters 
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include tailing factor, retention factor, theoretical plate number, 
retention time, asymmetry factor, selectivity factor and RSD of peak 
height or area for repeated injections. Typically, at least two of these 
criteria are required to demonstrate system suitability for the 
proposed method. Some of the tests were carried out on the freshly 
prepared standard solutions including two drugs. System suitability 




Fig. 2: System suitability 
 
Specificity 
The specificity of the method is performed by separate injections 
of the blank, ATV, EZT and combined ATV & EZT samples.  
 
The specificity chromatogram was shown in fig. 3, where the retention 
time of ATV does not interfere with the retention time of the EZT. 
  
 
Fig. 2: Typical specificity chromatograms: A) blank sample: B) EZT: C) ATV: D) Both ATV and EZT 
 
Linearity 
Linearity was established by least squares linear regression analysis 
of the calibration curve. The constructed calibration curves were 
linear over the concentration range of 5-50 µg/ml for both the 
drugs. Peak areas of ATV and EZT were plotted versus their 
respective concentrations in the mobile phase, and linear regression 
analysis performed on the resultant curves and was confirmed by 
the high value of the correlation coefficients 0.9983 & 0.998 for ATV 
and EZT respectively (table 2). Calibration curves of ATV and EZT 
Atla et al. 
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were shown in fig. 4 and 5. The LOD and LOQ were calculated from 
the following equations using the standard deviation (SD) of the 
response of the analyte (low concentration) and the slope (m) of the 
corresponding calibration curve:  
 
 
Limit of detection and quantification 
Limit of detection (LOD) and quantification (LOQ) was estimated 
from signal-to-noise ratio. The limit of detection (LOD) value was 
found to be 0.0035 µg/ml and 0.0078 µg/ml, and limit of 
quantification (LOQ) values was 0.0107 µg/ml and 0.0235 µg/ml for 
ATV and EZT respectively. 
 
Table 2: Statistical evaluation of the calibration data of ATV and 
EZT by LC 
Compounds ATV EZT 
Retention time, min 6.81 4.96 
Linearity range, µg/ml 5-50 5-50 
Slope 48147 63168 
Intercept 65564 52660 
Correlation coefficient 0.9983 0.998 
LOD, µg/ml 0.0035 0.00776 
LOQ, µg/ml 0.01069 0.0235 
Precision (RSD %) 1.206 0.93 
 
 
Fig. 4: Linearity graph for ATV 
 
Fig. 5: Linearity graph for EZT 
 
Precision 
Precision data is summarized in table 3 and was assessed by using 
quality control samples prepared at three different concentrations 
(LQC, MQC and HQC) in the mobile phase. Precision was investigated 
by injecting triplicate aliquots of the samples. All the data were 
within the acceptance criteria of 5%.  
Accuracy  
In order to demonstrate the accuracy, validity, and applicability of 
the proposed LC method, recovery tests were carried out by 
analyzing synthetic mixtures of ATV and EZT with different 
concentrations. Accuracy data for the assay following the 
determination of each of the compounds of interest are 
summarized in table 3. In each case, %RSD and accuracy 
(recovery) were calculated for each drug. All the data were within 
the acceptance criteria of 5% except in EZT concentrations of 
12.54 and 25.08 µg/ml, the % recovery was found to be 93.60 and 
92.65 respectively.  
Recovery 
The recovery analysis results were shown in table 3. The results of the 
recovery assay indicated that the method was selective, accurate and 
precise for both ATV and EZT, without the interference of excipients, 
used to formulate and produce the tablet dosage form studied.
 
Table 3: Accuracy and precision data 
 LQC MQC HQC 
 ATV EZT ATV EZT ATV EZT 
Mean 13.24 11.74 24.62 23.24 37.49 36.33 
SD 0.22 0.09 0.25 0.24 0.29 0.36 
% RSD 1.68 0.78 1.01 1.04 0.76 0.98 
% Recovery 105.26 93.60 97.84 92.65 99.37 96.56 
* Average of three injections each 
 
Table 4: Ruggedness studies of ATV and EZT 
 Drug Retention time (min) Tailing factor Theoretical plates 
Analyst 1 ATV 6.79 1.64 3402 
EZT 4.94 1.70 3209.33 
Analyst 2 ATV 6.81 1.63 3465 
EZT 4.97 1.69 3277 
* Average of three injections each 
 
Ruggedness 
Ruggedness was determined by using the data obtained by the 
analysis performed by two different analysts. Eac 
Robustness 
Robustness is the measure of method capacity to retain unaffected 
by deliberate small changes in the chromatographic conditions. The 
impact of flow rate (±0.1 ml) and effect of mobile phase composition 
(±5%) was evaluated on the important system suitability factors 
such as retention time, theoretical plates and tailing factor were 
studied. Results are shown in table 5. 
Stress testing studies 
The degradation product(s) of each of the parent compound was 
found to be same for mild stress conditions [35, 36]. Typical 
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chromatograms obtained for the control samples and stressed 
samples of ATV and EZT, using mild conditions are shown in fig. 6 A-
E and 7 A-E, respectively. Possible degradation products were 
observed in ATV and EZT stressed samples that were subjected to 
light, oxidation and acid and base hydrolysis under mild conditions. 
ATV and EZT were stable when exposed to UV light. ATV and EZT 
were clearly degraded during stress by oxidation, acid and alkaline 
hydrolysis (table 6) leading to the formation of some unknown 
degradation peaks (fig. 6 & 7). Peak purity test results derived from 
the UV detector confirmed that the ATV and EZT peaks were 
homogeneous and pure in nearly all analyzed stress samples. Both 
ATV and EZT responses were successfully resolved from 
degradation products with the proposed method, as shown in fig. 6 
and 7, respectively. 
 
Table 5: Robustness studies of ATV and EZT 
 Parameters Variation Retention time (min) Tailing factor Theoretical plates 
ATV Flow rate 0.9 ml/min 7.23 1.68 3666 
1.1 ml/min 6.06 1.65 3351 
Mobile phase 60 % organic phase 14.52 1.71 4180.33 
70 % organic phase 3.91 1.62 2743.67 
EZT Flow rate 0.9 ml/min 5.25 1.75 3372.67 
1.1 ml/min 4.42 1.72 3073.33 
Mobile phase 60 % organic phase 9.04 1.77 3820.33 
70 % organic phase 3.26 1.69 2517 
* Average of three injections 
 
Table 6: Results of hydrolytic (acidic and alkaline), oxidizing and photolytic mild stress conditions of ATV and EZT 
Response to mild conditions Peak area  Degradation of compounds, % a  
ATV EZT ATV EZT 
HCl (0.1M) 945790 1242175.5 14.91 9.70 
NaOH (0.1M) 1019736.5 932926.5 8.26 32.18 
H2O2 1022459.5 (3 %) 1341167 8.02 2.51 
UV (24 h) 1082105.5 1377870.5 2.65 0.16 
Control sample 1111576 1375683 - - 
a
 
Each value is the mean of three experiments 
 
Fig. 6: Typical degradation chromatograms of ATV; A) Control sample; B) 0.1 N HCL at 25 °C after 24 h; C) 0.1 N NaOH at 25 °C after 24 h; D) 
3 % H2O2 at 
 
Assay of Statix-Ex
25 °C after 24 h; E) UV light (210 nm) after 24 h 
®
After working on synthetic mixtures, results encouraged the use of 
the proposed method for the simultaneous assay of ATV and EZT in 
a commercial tablet dosage form. The results corresponding to the 
tablet dosage form of ATV and EZT are shown in table 3. The 
proposed RP-LC method could be used for the simultaneous 
determination of ATV and EZT in the presence of each other and 
without prior separation of the excipients. Each tablet contained 
10.0 mg ATV as atorvastatin calcium, 10.0 mg EZT as ezetimibe 
hydrochloride, and the inactive ingredients. Removal of the 
excipients before analysis was found to be unnecessary. fig. 8 shows 
a typical chromatogram obtained for the analysis of ATV and EZT in 
the tablets with well-shaped, symmetrical single peaks, well-
separated from the solvent front. No interfering peaks were 
obtained in the chromatogram due to tablet excipients. The 
determined amount of drugs indicates that the active ingredients in 
samples were present at level included within the requirements 
with respect to the label claimed by the manufacturer. The utility of 
the proposed method was verified by means of triplicate analyzes of 
the pharmaceutical preparation.  
 tablets  
Results obtained from the proposed method of the analysis of both 
drugs in the tablet formulation indicated that the proposed 
technique can be used for simultaneous quantification and routine 
QC analysis of this binary mixture in the pharmaceutical product. 
Atla et al. 




Fig. 7: Typical degradation chromatograms of EZT; A) Control sample; B) 0.1 N HCL at 25 °C after 24 h; C) 0.1 N NaOH at 25 °C after 24 h; D) 
3 % H2O2 at 
 
25 °C after 24 h; E) UV light (210 nm) after 24 h 
 




The composition, pH and flow rate of the mobile phase were 
changed to optimize the separation conditions using standard 
substances of the two drug analytes. In order to effect the 
simultaneous separation of the working compounds, mixtures of 
methanol and 0.1% v/v OPA in different combinations with different 
ratios and at various flow rates were evaluated. Finally, an RP 
Agilent Zorbax column (150 x 4.6 mm, 5 µm) and the mobile phase 
methanol: 0.1% v/v OPA (65:35) was found to be most suitable for 
LC analysis. A flow rate of 1.0 ml/min was selected for further 
studies after several preliminary investigatory chromatographic 
runs. The selected operating conditions were found to be optimal for 
sharp and symmetric peak shapes as well as to achieve minimal 
background noise. Under the described experimental conditions, all 
the peaks were well-defined and free from tailing. The proposed 
method was successfully used for the simultaneous determination of 
ATV and EZT in a tablet dosage form. 
With the optimized operating conditions, the retention times 
corresponding to ATV and EZT were 6.81 min and 4.96 min, 
respectively and were stable among injections. However, the analysis 
time was set to 10 min, allowing elution of possible excipients and 
degradation products that could be retained, without the need of a 
further stabilization time between injections. The proposed RP-LC 
method provided simple, simultaneous determination of the ATV and 
EZT in the drug by UV detection at 240 nm. After determining the 
optimum conditions, a satisfactory resolution was obtained in a short 
analysis time (about 7 min). For both the compounds, sharp, 
symmetrical and well-resolved peaks were obtained (fig. 2).  
Having optimized the efficiency of a chromatographic separation the 
quality of the chromatography was monitored by applying the 
system suitability tests. The acceptance criterion was±2% for the 
percent coefficient of variation for the peak area and retention times 
for ATV and EZT. The number of theoretical plates should not be less 
than 2500 and the tailing factor should not be more than 2.0. The 
peak purity of AZT and EZT were assessed by comparing the 
retention time (Rt) of standard and sample. A chromatogram 
obtained from reference substance solution is presented. The 
linearity range for AZT and EZT were found to be 5-50 µg/ml. The 
results of linearity studies are shown in table 2. Both precision and 
accuracy were determined with standard quality control samples 
prepared in triplicates at different concentration levels covering the 
linearity range. The repeatability and intermediate precision are 
reported as % RSD in table 3 and the minimum variation in the % 
RSD indicate that the present method is precise. The accuracy of the 
proposed method was assessed by adding known amount of the 
Atla et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 4, 370-377 
 
376 
drug to a drug solution of known concentration and subjecting the 
samples to the proposed HPLC method. All solutions were prepared 
and analyzed in triplicate. The above procedure is adopted for AZT 
and EZT with high recovery values obtained (table 3) indicate that 
the proposed method is highly accurate. To evaluate the robustness 
of the developed RP-HPLC method, small deliberate variations in the 
optimized method parameters were done. The effect of a change in 
flow rate, pH and mobile phase ratio on the retention time and 
tailing factor were studied. The values for proposed method are well 
within acceptance limits with a % RSD of less than 2.0. Above 
experiments indicated that the method is rugged and provides 
consistent and reliable results. The method specificity was assessed 
by studying the chromatograms obtained for a mixture of the drugs 
and the common excipients. As none of the excipients interfered 
with the analytes of interest, the method was found to be suitable for 
analyzing the commercial formulation of these drugs. 
CONCLUSION 
A simple, rapid, accurate, and precise stability-indicating RP-LC 
method has been developed and validated for routine analysis of 
ATV and EZT standard samples and a tablet dosage form. Using the 
described chromatographic conditions, ATV and EZT were well-
separated. The proposed method gives good resolution between 
selected compounds within short analysis time. The method 
developed would serve as a versatile analytical tool suitable for the 
simultaneous analysis of the drugs in the tested formulation and 
would be of interest for QC and clinical monitoring laboratories. 
Recovery studies exhibited that the method was free from interference 
by the excipients in the tablet dosage form. The results of stress testing 
undertaken according to the ICH guidelines revealed that the method 
is selective and stability-indicating. The proposed RP-LC method can 
be used for the routine analysis of production samples and to check 
the stability of bulk samples of ATV and EZT. 
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